{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:25:48Z","timestamp":1793330748290,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Practice patterns of hydroxychloroquine retinopathy screening have not yet been reported at a national level in South Korea.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the practice patterns of timing and modality for hydroxychloroquine retinopathy screening in South Korea.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This nationwide population-based cohort study of patients in South Korea used data from the national Health Insurance Review and Assessment database. Patients at risk were identified as those who had initiated hydroxychloroquine therapy between January 1, 2009, and December 31, 2020, and used it for 6 months or more. Patients were excluded if they underwent any of the 4 screening modalities recommended by the American Academy of Ophthalmology (AAO) for other ophthalmic diseases prior to hydroxychloroquine use. The timing and modalities of screening used in baseline and monitoring examinations were assessed between January 1, 2015, and December 31, 2021, among patients at risk and long-term (\u22655 years) users.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Adherence of baseline screening practices to the 2016 AAO recommendations (fundus examination within 1 year of drug use) was evaluated; adherence of monitoring examinations in year 5 was classified as appropriate (\u22652 tests recommended by the AAO), unscreened (no test performed), and underscreened (insufficient number of tests).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Timing of screening and modalities used at baseline and monitoring examinations.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 65\u202f406 patients at risk (mean [SD] age, 53.0 [15.5] years; 50\u202f622 women [77.4%]) were included; 29\u202f776 patients were long-term users (mean [SD] age, 50.1 [14.7] years; 24\u202f898 women [83.6%]). Baseline screening was performed for 20.8% of the patients within 1 year, with a gradual increase from 16.6% in 2015 to 25.6% in 2021. Monitoring examinations, mostly using optical coherence tomography and\/or visual field tests, were performed for only 13.5% of the long-term users in year 5 and for 31.6% of the long-term users after 5 years. Appropriate monitoring was performed for less than 10% of long-term users each year from 2015 to 2021; however, the percentage gradually increased over time. The percentage of patients undergoing any monitoring examination in year 5 was 2.3 times greater for those who had received baseline screening than for those who did not (27.4% vs 11.9%; P<\/jats:italic>\u2009&amp;lt;\u2009.001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study suggests there is an improving trend in retinopathy screening among hydroxychloroquine users in South Korea; however, most long-term users remained unscreened after 5 years of use. Baseline screening may be useful in reducing the number of unscreened long-term users.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.14816","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:03:56Z","timestamp":1684854236000},"page":"e2314816","source":"Crossref","is-referenced-by-count":26,"title":["Practice Patterns of Screening for Hydroxychloroquine Retinopathy in South Korea"],"prefix":"10.1001","volume":"6","author":[{"given":"Jiyeong","family":"Kim","sequence":"first","affiliation":[{"name":"Biostatistical Consulting and Research Lab, Industry-University Cooperation Foundation, Hanyang University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko Eun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Joon","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"issue":"9","key":"zoi230454r1","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).","volume":"66","author":"Alarc\u00f3n","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi230454r2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus.","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"zoi230454r3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/acr.v72.1","article-title":"Clinical and structural efficacy of hydroxychloroquine in rheumatoid arthritis: a systematic review.","volume":"72","author":"Rempenault","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1A","key":"zoi230454r4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate.","volume":"75","author":"McChesney","year":"1983","journal-title":"Am J Med"},{"issue":"4","key":"zoi230454r5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00007691-198907000-00001","article-title":"Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine.","volume":"11","author":"Titus","year":"1989","journal-title":"Ther Drug Monit"},{"issue":"6","key":"zoi230454r6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision).","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"zoi230454r8","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0161-6420(02)01168-5","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology.","volume":"109","author":"Marmor","year":"2002","journal-title":"Ophthalmology"},{"issue":"2","key":"zoi230454r9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"zoi230454r10","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/s41433-020-01380-2","article-title":"The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary.","volume":"35","author":"Yusuf","year":"2021","journal-title":"Eye (Lond)"},{"issue":"3","key":"zoi230454r11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ajo.2015.06.009","article-title":"Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice.","volume":"160","author":"Au","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"zoi230454r12","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/bjo.2008.144402","article-title":"Hydroxychloroquine retinopathy screening.","volume":"92","author":"Semmer","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"zoi230454r13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/jamaophthalmol.2014.1720","article-title":"Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.","volume":"132","author":"Nika","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"zoi230454r14","doi-asserted-by":"publisher","first-page":"A3","DOI":"10.1016\/j.ajo.2020.03.028","article-title":"COVID-19 and chloroquine\/hydroxychloroquine: is there ophthalmological concern?","volume":"213","author":"Marmor","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"zoi230454r15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ajo.2015.07.012","article-title":"Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy.","volume":"160","author":"Leung","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"20","key":"zoi230454r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"zoi230454r17","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ophtha.2020.10.029","article-title":"Long-term progression of pericentral hydroxychloroquine retinopathy.","volume":"128","author":"Ahn","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"zoi230454r18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ophtha.2014.07.018","article-title":"Pericentral retinopathy and racial differences in hydroxychloroquine toxicity.","volume":"122","author":"Melles","year":"2015","journal-title":"Ophthalmology"},{"issue":"6","key":"zoi230454r19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.ophtha.2015.01.014","article-title":"Pericentral hydroxychloroquine retinopathy in Korean patients.","volume":"122","author":"Lee","year":"2015","journal-title":"Ophthalmology"},{"key":"zoi230454r20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2022.07.028","article-title":"Macular ganglion cell complex and peripapillary retinal nerve fiber layer thicknesses in hydroxychloroquine retinopathy.","volume":"245","author":"Kim","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"zoi230454r21","doi-asserted-by":"publisher","first-page":"11809","DOI":"10.1038\/s41598-022-15217-3","article-title":"Clock-hour topography and extent of outer retinal damage in hydroxychloroquine retinopathy.","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"key":"zoi230454r22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ajo.2019.09.008","article-title":"Evaluation of hydroxychloroquine retinopathy using ultra-widefield fundus autofluorescence: peripheral findings in the retinopathy.","volume":"209","author":"Ahn","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"zoi230454r23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2018.11.003","article-title":"En face optical coherence tomography imaging of the photoreceptor layers in hydroxychloroquine retinopathy.","volume":"199","author":"Ahn","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"zoi230454r24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2017.09.025","article-title":"Optical coherence tomography protocols for screening of hydroxychloroquine retinopathy in Asian patients.","volume":"184","author":"Ahn","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"zoi230454r25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"zoi230454r7","author":"Browning","year":"2014"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2805171\/kim_2023_oi_230454_1683899157.60194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:03:58Z","timestamp":1684854238000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2805171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14816","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}